posted on 2023-02-23, 15:10authored bySuzanne S. Dunne, Bill Shannon, Walter Cullen, Colum P. DunneColum P. Dunne
BACKGROUND: Following the enactment of legislation in June 2013, generic
substitution and reference pricing of medicines has been introduced, for
the first time, in Ireland. This novel study is the first assessment of the perceptions
of community pharmacists in Ireland towards generic medicines
completed in the period immediately prior to the introduction of generic
substitution and reference pricing.
OBJECTIVE: To determine the perceptions towards generic medicines
among community pharmacists.
METHODS: One-to-one semistructured interviews were performed with a
convenience sample of 44 community pharmacists (from approximately
4,500 pharmacists in Ireland) recruited from Ireland’s Midwest, South, and
Southwest regions. Interviews were transcribed and analysed using NVivo
(version 9).
RESULTS: 98% of pharmacists believed that generics were of a similar
quality to the originator, and 96% stated that they were as effective as
the originator. However, a small number demonstrated some reticence
regarding generics: 9% believed that generics were not manufactured to
the same quality as the originator; 7% stated they would prefer to take
an originator medicine themselves; and 7% reported having experienced
quality issues with generic medicines. 89% of pharmacists reported receiving
patient complaints regarding use of generic medicine, although 64%
suggested that this was due to a nocebo effect (i.e., a result of patients’
preconceived notions that generics were inferior). Only a minority (21%)
reported that they had attempted to educate patients as to the equivalency
of generics. Although 80% were in favor of Ireland’s new legislation promoting
the use generic medicines, 46% expressed concerns regarding its
practical implementation.
CONCLUSIONS: This key stakeholder group had positive attitudes towards
generics and the legislation that promotes their use. Concerns regarding
patient perception and experience, clinical effectiveness, and manufacturing
quality were identified. We propose that interventions supporting implementation
of the new legislation should address these concerns.
History
Publication
Journal of Managed Care and Speciality Pharmacy;20 (11), pp. 1138-1146
Publisher
Academy of Managed Care Pharmacy
Note
peer-reviewed
Language
English
Also affiliated with
4i - Centre for Interventions in Infection, Inflammation & Immunity